

Company Contact:
Elizabeth Hutt
Vice President, Commercial Operations
650-590-3600
ehutt@nugeninc.com

Media Contact:
Carolyn Hawley
Atkins + Associates for NuGEN Technologies
858-527-3484
chawley@irpr.com

NuGEN Enters Into Collaboration with Consortium of Healthcare Organizations

San Carlos, California – March 8, 2005 – NuGEN Technologies, Inc., a privately held company developing and commercializing the new standard in nucleic acid amplification and labeling systems, announced an agreement between the company and AMDeC Foundation, Inc., a non-profit consortium of over 30 healthcare organizations, research institutions and medical schools in New York State, wherein NuGEN will provide RNA amplification systems to the member institutions, sponsorship for key AMDeC initiatives and statewide on-site training programs.

NuGEN offers three Ovation™ Systems for amplifying and labeling RNA for gene expression analysis. The Ovation Biotin System is validated for use with Affymetrix GeneChip® arrays, the Ovation Aminoallyl System is used with spotted oligo or cDNA arrays, and the Ovation RNA Amplification System is designed to amplify RNA prior to quantitative real-time PCR (QPCR). The Systems are powered by NuGEN's proprietary Ribo-SPIA™ technology, which enables rapid, simple and sensitive RNA amplification for gene expression analysis.

"We have been working with NuGEN's Ovation kits for several months now and are very happy with the results that we have been getting with our Affymetrix GeneChip microarray experiments," said Jenny Xiang, M.D., director of the Weill Cornell Medical College Microarray Core Facility. "Ovation kits generate cDNA that allow us to obtain exceptionally high quality microarray results, and we've been recommending their use to our Microarray Core Facility users. Now that NuGEN has an agreement with AMDeC, our facility users will be able to obtain the kits more easily and economically than before."

"The alliance agreement helps further AMDeC's mission to promote biomedical research in New York," said Maria Mitchell, Ph.D., president AMDeC. AMDeC is a non-profit organization whose members include more than 30 premier healthcare organizations, medical schools and research institutions in New York State. AMDeC receives grant contributions from government entities and corporate foundations and funds biomedical and genomics-related research activities and initiatives managed by AMDeC and undertaken by AMDeC-affiliated institutions. Among the members of AMDeC are Memorial Sloan Kettering Cancer Center, Mount Sinai School of Medicine, Weill Medical College of Cornell University and University of Rochester Medical Center.

"Our collaboration with AMDeC will give us greater visibility at many New York State medical research institutions and further solidify our reputation as a significant emerging company in the functional genomics market place. We are really excited to have AMDeC join our growing list of important, international life science research clients," commented Elizabeth Hutt, vice president of commercial operations.

About NuGEN Technologies Inc.

NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA™ and Ribo-SPIA™ amplification and labeling technology for DNA and RNA based applications, form the

foundation for a wide range of methods and products used by life scientists. The Ovation™ amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.

NuGEN, Ovation, SPIA and Ribo-SPIA are trademarks or service marks of NuGEN Technologies, Inc.

This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

###